1
|
Guo Y, Wu H, Wiesmüller L, Chen M. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell Death Dis 2024; 15:412. [PMID: 38866752 PMCID: PMC11169513 DOI: 10.1038/s41419-024-06783-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Revised: 05/26/2024] [Accepted: 05/28/2024] [Indexed: 06/14/2024]
Abstract
Full-length p53 (p53α) plays a pivotal role in maintaining genomic integrity and preventing tumor development. Over the years, p53 was found to exist in various isoforms, which are generated through alternative splicing, alternative initiation of translation, and internal ribosome entry site. p53 isoforms, either C-terminally altered or N-terminally truncated, exhibit distinct biological roles compared to p53α, and have significant implications for tumor development and therapy resistance. Due to a lack of part and/or complete C- or N-terminal domains, ectopic expression of some p53 isoforms failed to induce expression of canonical transcriptional targets of p53α like CDKN1A or MDM2, even though they may bind their promoters. Yet, p53 isoforms like Δ40p53α still activate subsets of targets including MDM2 and BAX. Furthermore, certain p53 isoforms transactivate even novel targets compared to p53α. More recently, non-canonical functions of p53α in DNA repair and of different isoforms in DNA replication unrelated to transcriptional activities were discovered, amplifying the potential of p53 as a master regulator of physiological and tumor suppressor functions in human cells. Both regarding canonical and non-canonical functions, alternative p53 isoforms frequently exert dominant negative effects on p53α and its partners, which is modified by the relative isoform levels. Underlying mechanisms include hetero-oligomerization, changes in subcellular localization, and aggregation. These processes ultimately influence the net activities of p53α and give rise to diverse cellular outcomes. Biological roles of p53 isoforms have implications for tumor development and cancer therapy resistance. Dysregulated expression of isoforms has been observed in various cancer types and is associated with different clinical outcomes. In conclusion, p53 isoforms have expanded our understanding of the complex regulatory network involving p53 in tumors. Unraveling the mechanisms underlying the biological roles of p53 isoforms provides new avenues for studies aiming at a better understanding of tumor development and developing therapeutic interventions to overcome resistance.
Collapse
Affiliation(s)
- Yitian Guo
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China.
| | - Hang Wu
- Department of Rehabilitation Medicine, Zhongda Hospital Southeast University, Nanjing, China
| | - Lisa Wiesmüller
- Department of Obstetrics and Gynecology, Ulm University, Ulm, Germany
| | - Ming Chen
- Department of Urology, Zhongda Hospital Southeast University, Nanjing, China.
| |
Collapse
|
2
|
Ray Das S, Delahunt B, Lasham A, Li K, Wright D, Print C, Slatter T, Braithwaite A, Mehta S. Combining TP53 mutation and isoform has the potential to improve clinical practice. Pathology 2024; 56:473-483. [PMID: 38594116 DOI: 10.1016/j.pathol.2024.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 01/21/2024] [Accepted: 02/06/2024] [Indexed: 04/11/2024]
Abstract
The clinical importance of assessing and combining data on TP53 mutations and isoforms is discussed in this article. It gives a succinct overview of the structural makeup and key biological roles of the isoforms. It then provides a comprehensive summary of the roles that p53 isoforms play in cancer development, therapy response and resistance. The review provides a summary of studies demonstrating the role of p53 isoforms as potential prognostic indicators. It further provides evidence on how the presence of TP53 mutations may affect one or more of these activities and the association of p53 isoforms with clinicopathological data in various tumour types. The review gives insight into the present diagnostic hurdles for identifying TP53 isoforms and makes recommendations to improve their evaluation. In conclusion, this review offers suggestions for enhancing the identification and integration of TP53 isoforms in conjunction with mutation data within the clinical context.
Collapse
Affiliation(s)
- Sankalita Ray Das
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
| | - Brett Delahunt
- Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand
| | - Annette Lasham
- Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand; Te Aka Mātauranga Matepukupuku (Centre for Cancer Research), University of Auckland, Auckland, New Zealand
| | - Kunyu Li
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
| | - Deborah Wright
- Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
| | - Cristin Print
- Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand; Te Aka Mātauranga Matepukupuku (Centre for Cancer Research), University of Auckland, Auckland, New Zealand
| | - Tania Slatter
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
| | - Antony Braithwaite
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand
| | - Sunali Mehta
- Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; Maurice Wilkins Centre for Biodiscovery, University of Auckland, Auckland, New Zealand.
| |
Collapse
|
3
|
p53 Isoforms as Cancer Biomarkers and Therapeutic Targets. Cancers (Basel) 2022; 14:cancers14133145. [PMID: 35804915 PMCID: PMC9264937 DOI: 10.3390/cancers14133145] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 06/22/2022] [Indexed: 02/04/2023] Open
Abstract
Simple Summary The well-known tumor suppressor protein p53 plays important roles in tumor prevention through transcriptional regulation of its target genes. Reactivation of p53 activity has been a potent strategy for cancer treatment. Accumulating evidences indicate that p53 isoforms truncated/modified in the N- or C-terminus can modulate the p53 pathway in a p53-dependent or p53-independent manner. It is thus imperative to characterize the roles of the p53 isoforms in cancer development. This review illustrates how p53 isoforms participate in tumor development and/or suppression. It also summarizes the knowledge about the p53 isoforms as promising cancer biomarkers and therapeutic targets. Abstract This review aims to summarize the implications of the major isoforms of the tumor suppressor protein p53 in aggressive cancer development. The current knowledge of p53 isoforms, their involvement in cell-signaling pathways, and their interactions with other cellular proteins or factors suggests the existence of an intricate molecular network that regulates their oncogenic function. Moreover, existing literature about the involvement of the p53 isoforms in various cancers leads to the proposition of therapeutic solutions by altering the cellular levels of the p53 isoforms. This review thus summarizes how the major p53 isoforms Δ40p53α/β/γ, Δ133p53α/β/γ, and Δ160p53α/β/γ might have clinical relevance in the diagnosis and effective treatments of cancer.
Collapse
|
4
|
Rojas EA, Corchete LA, De Ramón C, Krzeminski P, Quwaider D, García‐Sanz R, Martínez‐López J, Oriol A, Rosiñol L, Bladé J, Lahuerta JJ, San Miguel JF, González M, Mateos MV, Bourdon J, Misiewicz‐Krzeminska I, Gutiérrez NC. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. Am J Hematol 2022; 97:700-710. [PMID: 35188691 PMCID: PMC9313569 DOI: 10.1002/ajh.26507] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 01/21/2022] [Accepted: 02/15/2022] [Indexed: 12/20/2022]
Abstract
Loss and/or mutation of the TP53 gene are associated with short survival in multiple myeloma, but the p53 landscape goes far beyond. At least 12 p53 protein isoforms have been identified as a result of a combination of alternative splicing, alternative promoters and/or alternative transcription site starts, which are grouped as α, β, γ, from transactivation domain (TA), long, and short isoforms. Nowadays, there are no studies evaluating the expression of p53 isoforms and its clinical relevance in multiple myeloma (MM). We used capillary nanoimmunoassay to quantify the expression of p53 protein isoforms in CD138-purified samples from 156 patients with newly diagnosed MM who were treated as part of the PETHEMA/GEM2012 clinical trial and investigated their prognostic impact. Quantitative real-time polymerase chain reaction was used to corroborate the results at RNA levels. Low and high levels of expression of short and TAp53β/γ isoforms, respectively, were associated with adverse prognosis in MM patients. Multivariate Cox models identified high levels of TAp53β/γ (hazard ratio [HR], 4.49; p < .001) and high-risk cytogenetics (HR, 2.69; p < .001) as independent prognostic factors associated with shorter time to progression. The current cytogenetic-risk classification was notably improved when expression levels of p53 protein isoforms were incorporated, whereby high-risk MM expressing high levels of short isoforms had significantly longer survival than high-risk patients with low levels of these isoforms. This is the first study that demonstrates the prognostic value of p53 isoforms in MM patients, providing new insights on the role of p53 protein dysregulation in MM biology.
Collapse
Affiliation(s)
- Elizabeta A. Rojas
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
| | - Luis A. Corchete
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
| | - Cristina De Ramón
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
| | - Patryk Krzeminski
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
- Department of Nanobiotechnology and Experimental Ecology, Institute of Biology Warsaw University of Life Sciences Warsaw Poland
| | - Dalia Quwaider
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
| | - Ramón García‐Sanz
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233 Salamanca Spain
- Grupo Español de Mieloma (GEM) Barcelona Spain
| | - Joaquín Martínez‐López
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233 Salamanca Spain
- Grupo Español de Mieloma (GEM) Barcelona Spain
- Medicine Department Complutense University Madrid Spain
- Spanish National Cancer Research Center (CNIO) Madrid Spain
| | - Albert Oriol
- Grupo Español de Mieloma (GEM) Barcelona Spain
- University Hospital Germans Trias i Pujol Barcelona Spain
| | - Laura Rosiñol
- Grupo Español de Mieloma (GEM) Barcelona Spain
- Hospital Clinic of Barcelona Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Barcelona Spain
| | - Joan Bladé
- Grupo Español de Mieloma (GEM) Barcelona Spain
- Hospital Clinic of Barcelona Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS) Barcelona Spain
| | - Juan José Lahuerta
- Grupo Español de Mieloma (GEM) Barcelona Spain
- Hematology Department University Hospital 12 de Octubre Madrid Spain
| | - Jesús F. San Miguel
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233 Salamanca Spain
- Grupo Español de Mieloma (GEM) Barcelona Spain
- Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas (CIMA) Instituto de Investigación Sanitaria de Navarra (IdiSNA) Pamplona Spain
| | - Marcos González
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233 Salamanca Spain
| | - María Victoria Mateos
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233 Salamanca Spain
- Grupo Español de Mieloma (GEM) Barcelona Spain
| | | | - Irena Misiewicz‐Krzeminska
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
- Experimental Hematology Department Institute of Hematology and Transfusion Medicine Warsaw Poland
| | - Norma C. Gutiérrez
- Hematology Department University Hospital of Salamanca, IBSAL Salamanca Spain
- Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233 Salamanca Spain
- Grupo Español de Mieloma (GEM) Barcelona Spain
| |
Collapse
|